Express Pharma
Home  »  Market  »  IPM clocks Rs 115,725 Cr in June 2017

IPM clocks Rs 115,725 Cr in June 2017

Read Article

Dermatology continued to be the second fastest growing therapy area

The Indian Pharmaceutical Market (IPM) clocked Rs 115,725 crores of which the retail sector was valued at Rs 97,208 crores as of MAT June 2017 with a monthly value of Rs 9215 crores with a growth of 0.3 per cent over the last year.

The share of top 10 companies continued to be 43 per cent in the IPM and these top companies grew at just one per cent over SPLY. Out of the Top 10 companies only Mankind (11 per cent) and Lupin (nine per cent) recorded a positive growth for the month. The growth for companies in the 11-20 and 21-30 bracket was in negative for the month with these companies recording (-1 per cent) and (-3 per cent) growth respectively. Overall only nine of the top 30 companies showed a positive growth with MSD showing the highest growth at 12 per cent.

Top 40 Brands

Source: QuintilesIMS TSA & SSA, June 2017
  • Mixtard continues to be the top brand with a MS of 0.5%
  • Betnovate-C, Lantus, Januvia and Duphaston have shown phenomenal growths in June 2017
  • Other brands with remarkable growth are Janumet, Spasmo-Proxyvon+, Synflorix, Dolonex, Istamet and Udiliv

The decline in growth of top companies as well as of whole IPM has been a result of GST implementation which was due on July 1, 2017. Though the long-term impact of GST on IPM remains positive, there has been some short-term disruption observed. 50 per cent-70 per cent of stockists/ chemists weren’t clear and hadn’t initiated on implementation of GST in their businesses leading to inventory rationalisation by stockists due to which most pharma companies closed their sales for the month earlier than usual which had an impact on their overall sales.

The impact can be seen of the Top 10 brands of IPM too where these brands which are valued at Rs 306 crores have shown a combined single digit growth at 8 per cent over last year. However, Lantus (30 per cent), Janumet (16 per cent) and Spasmo-Proxyvon (19 per cent) continue to show strong growths while Mixtard and Glycomet-GP continues to maintain number one and number two positions and growths of eight per cent and five per cent respectively. Among top five brands, Lantus has displaced Janumet to take the third position. Also, within brands ranked between five and 10, Galvus Met has come down two places and is now ranked eighth as compared to its sixth rank in May. The impact has been more on brands ranked 11-20 where seven brands recorded a negative growth with only Duphaston (26 per cent), Shelcal (7 per cent) and Synflorix (23 per cent) shown a progressive trend.

Acute and Chronic Therapies

Source: QuintilesIMS TSA & SSA, June 2017
  • Acute therapies continue to dominate the market constituting 65% of the IPM
  • The top TC4 in the IPM is DPP4 Inhibitor and Combination with a value growth of 19%

Indian companies increased their share by  one per cent as compared to May and now have a share of 79 per cent in the IPM and grew at par with the market at 0.4 per cent. Number one MNC Abbott (-0.1 per cent) recorded a slower than market growth where as other top 10 MNCs like Sanofi (five per cent), MSD (12 per cent) and Eli Lily (four per cent) showed a positive and better than market growth for the month. Overall MNCs recorded a growth of (- 0.2 per cent).

Chronic therapy grew at three per cent and registered a better growth as compared to acute therapy (0.5 per cent) which continues to dominate the IPM with 65 per cent share. Cardiac remains the largest therapy for the month of June with a growth of one per cent while anti-infectives jumped one rank above and displaced gastro intestinal to become the second largest therapy. Antidiabetic (10 per cent) showed the strongest growth among all therapy areas and was valued at Rs 890 crores for the month. DPP IV Inhibitors and combination continued to be the number one therapeutic class 4 with a robust 19 per cent growth. However, many of the top 10 therapeutic class 4 like food supplements (-1 per cent), Amoxycillin and Clavulinic Acid Solids (-13 per cent) and conventional iron liquid (-3 per cent) recorded de-growth for the month. Cardiac therapy continues to be the number one therapy for the month with a revenue of Rs 1102 crores and a growth rate of one per cent. Even though top combination molecules like Telmisartan+ HCT (six per cent), Amlodipine+ Telmisartan (11 per cent) and Metoprolol+ Telmisartan (17 per cent) have shown strong growths, the overall growth is being pulled down by plain molecules like Atorvastatin (-20 per cent), Telmisartan (-5 per cent) and Metoprolol (-8 per cent). However, few single molecules like Rosuvastatin (two per cent) and Cilnidipine (15 per cent) have shown progressive trend. This trend can also be seen where overall combinations in cardiac therapy have grown at six per cent as compared to plain molecules which have shown a growth of (-1 per cent).

Therapy Trends

Source: QuintilesIMS TSA & SSA, June 2017
  • Cardiac therapy and Anti Infectives constitute the largest market share in IPM occupying 12% share each
  • Anti Diabetics and Vaccines registered a growth of around 10% and 9% respectively for the same period last year
  • Vaccines and Oncology market have grown by 1% and 5% respectively, while rest of the therapies have de-grown over previous month

Anti infective therapy area is valued at Rs 1075 crores for the month of June and has regained its second position below cardiac after it lost the position to gastro intestinal in April. However, its growth continues to be slower than the market and has gone down for the month (-6 per cent) which is the lowest among top 10 therapy areas. Most of the top 10 molecules like Amoxycillin and Clavulinic Acid Solids (-13 per cent), Ceftriaxone Injectables (-15 per cent) and Cefixime Oral Solids (-20 per cent) have shown a double digit negative growth with only Meropenam (12 per cent) and Ceftriaxone+Salbactum (28 per cent) showing a progressive growth trend.

Gastro intestinal therapy area lost its second position which it had gained two months back to anti-infective. Gastro intestinal is valued at Rs 1043 crores for the month with de-growth of -2 per cent. Even though its largest molecule Pantoprazole+Domperid clocked Rs 63 crores for the month and showed a decent growth of 2 per cent, seven other molecules among top 10 recorded a negative growth to pull down the overall growth of the therapy. However, Bacillus Clausii continued its progressive trend and grew at 30 per cent for the month. Among brands, Spasmo-Proxyvon showed a robust growth of 19 per cent and continued to be the top brand in the therapy at both month and MAT level. Anti-diabetics maintained its fourth position in the IPM for the month of June 2017 and was the fastest growing therapy area with a growth of 10 per cent over SPLY. All top four brands in the IPM belong to this category and with robust growths. DPP4 Inhibitors continue to dominate with a 23 per cent contribution to the entire category while SGLT2 Inhibitor is the growth driver with a growth rate of 111 per cent for the month. Except for Metformin showing a negative growth (-11 per cent) and Glicalzide+Metformin showing a stagnant zero per cent growth, all other Top 10 molecules have grown strongly which has led to progress of the therapy. All of the top 10 brands except Novomix (zero per cent) have shown robust growth with Lantus (30 per cent) and Januvia (30 per cent) leading the growth charts. Vitamins-Minerals-Nutrients (VMN) continues to be the fifth largest therapy area for the month but with a diminished growth of -1.3 per cent. This is mainly due to six of its top 10 molecules, which contribute around 40 per cent to the therapy, have de-grown at a combined rate of -4 per cent. Food supplements is the top segment within the therapy with a value of Rs 136 crores and grew at -1 per cent. Becosules showed a growth of -2 per cent and continues to be the top brand in the therapy while the number two brand Shelcal grew robustly at 7 per cent for the month of June 2017. Revital-H (-33 per cent) showed the highest de-growth amongst top brands and moved down 2 ranks from fourth to sixth in the therapy.

Dermatology continued to be the second fastest growing therapy area in IPM with a growth of eight per cent SPLY and a value of Rs 669 crores for the month of June 2017. Emollients remains the largest sub category with a three per cent growth while the growth is driven by Itraconazole which continues to be the fastest growing molecule at robust growth rate of 96 per cent for the month. Luliconazole, which was launched just last year, has continued its impressive performance by clocking Rs 17.3 crores for the month. Among brands, even though the top brand Betadine showed a regressive growth of -4 per cent, other top 10 brands like Betnovate-C (41per cent), Betnovate-N (26 per cent), Panderm+ (35 per cent), Candiforce (85 per cent) and IT-Mac (146 per cent) ensured progressive growth for the therapy.

Global (May 2017)

The global pharma market is valued at $1079 billion growing at 4.4 per cent. The US continues to dominate the market with 40 per cent market share with growth of 1.2 per cent.

Amongst the top market, India remains at the same position and is ranked 11th. Only markets in the top markets with more than 10 per cent growth are Venezuela, India, Russia and Brazil. Except Germany, the remaining Top 5 EU markets are all de-growing as per May 2017 data. Indian companies hold 1.6 per cent share in the global market as per May 2017 data. For the month of May 2017, the IPM showed growth and all Top 10 companies showed growth. Top 10 companies contribute to 42 per cent market share in India.

Comments are closed.